Drugs / MTX-439
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07473323 | May 2026 → May 2027 expected | diabetic kidney disease | Mediar Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX-439 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07473323 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody (mAb)” NCT07473323 ↗ |
| Route | Intravenous | “intravenous (IV) dosing” NCT07473323 ↗ |
| Target | SMOC2 | “binds human-secreted protein SMOC2” NCT07473323 ↗ |